Diffuse Cutaneous Bullous Mastocytosis and Disseminated Intravascular Coagulation Postvaccination: A Case Report
Alexandra Hudson1, Laura Finlayson2,3
1Dalhousie Medicine, Halifax, Nova Scotia, Canada alexandra.hudson@dal.ca.
Journal of Cutaneous Medicine and Surgery
|July 21, 2016
Summary
Diffuse cutaneous bullous mastocytosis, a rare skin condition, can cause severe blistering and complications. Optimal medical management is crucial for managing symptoms like urtication and flushing over time.
Area of Science:
- Dermatology
- Pediatric Hematology
- Rare Diseases
Background:
- Diffuse cutaneous bullous mastocytosis (DCBM) is an exceptionally rare subtype of cutaneous mastocytosis.
- Characterized by widespread skin infiltration by mast cells and the development of blisters.
Observation:
- A male infant diagnosed with DCBM on day 7 of life was monitored for 6 years.
- At 2.5 months, post-vaccination blistering flare led to disseminated intravascular coagulation and acute tubular necrosis.
- Blistering resolved by age 3, but urtication persisted at age 6.
Findings:
- The case illustrates the long-term progression of DCBM over 6 years.
- Complications included disseminated intravascular coagulation and acute tubular necrosis following a blistering flare.
- Persistent urtication at age 6 suggests a need for optimized pharmacologic treatment.
Implications:
- Highlights the importance of early diagnosis and comprehensive management of rare cutaneous conditions.
- Emphasizes the need for optimal pharmacologic blockage of histamine receptors and mast cell membrane stabilization.
- Underscores the potential for severe complications and chronic symptoms in DCBM patients.
